NI201100196A - Respuesta inmunitaria reforzada en especies aviares - Google Patents

Respuesta inmunitaria reforzada en especies aviares

Info

Publication number
NI201100196A
NI201100196A NI201100196A NI201100196A NI201100196A NI 201100196 A NI201100196 A NI 201100196A NI 201100196 A NI201100196 A NI 201100196A NI 201100196 A NI201100196 A NI 201100196A NI 201100196 A NI201100196 A NI 201100196A
Authority
NI
Nicaragua
Prior art keywords
avian species
immune response
enhanced immune
infectious disease
effective
Prior art date
Application number
NI201100196A
Other languages
English (en)
Inventor
Abraham Albert
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of NI201100196A publication Critical patent/NI201100196A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un procedimiento de activación inmunitaria que es eficaz para provocar una respuesta inmunitaria no específica de antígeno en un miembro de las especies aviares. El procedimiento es particularmente eficaz para proteger a un miembro de las especies aviares de enfermedad infecciosa y para tratar animales afectados con enfermedad infecciosa.
NI201100196A 2009-05-14 2011-11-11 Respuesta inmunitaria reforzada en especies aviares NI201100196A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17809909P 2009-05-14 2009-05-14

Publications (1)

Publication Number Publication Date
NI201100196A true NI201100196A (es) 2012-06-06

Family

ID=42357738

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100196A NI201100196A (es) 2009-05-14 2011-11-11 Respuesta inmunitaria reforzada en especies aviares

Country Status (35)

Country Link
US (1) US20120064151A1 (es)
EP (2) EP2992899B1 (es)
JP (1) JP5679589B2 (es)
KR (2) KR101966989B1 (es)
CN (2) CN104906573A (es)
AR (1) AR076767A1 (es)
AU (1) AU2010246652B2 (es)
BR (1) BRPI1010803A2 (es)
CA (1) CA2761736C (es)
CL (1) CL2011002808A1 (es)
CO (1) CO6460752A2 (es)
CR (1) CR20110595A (es)
DK (2) DK2992899T3 (es)
EC (1) ECSP11011448A (es)
ES (2) ES2808827T3 (es)
HK (1) HK1168032A1 (es)
HR (2) HRP20151117T1 (es)
HU (2) HUE025765T2 (es)
IL (1) IL215900A (es)
LT (1) LT2992899T (es)
MX (1) MX336019B (es)
MY (1) MY162561A (es)
NI (1) NI201100196A (es)
NZ (1) NZ596366A (es)
PE (1) PE20120903A1 (es)
PL (2) PL2992899T3 (es)
PT (2) PT2992899T (es)
RU (1) RU2570732C9 (es)
SI (2) SI2992899T1 (es)
SV (1) SV2011004056A (es)
TW (1) TWI555846B (es)
UA (1) UA106076C2 (es)
UY (1) UY32634A (es)
WO (1) WO2010130374A1 (es)
ZA (1) ZA201107827B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945590B2 (en) * 2008-03-25 2015-02-03 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)
WO2012084951A1 (en) * 2010-12-22 2012-06-28 Bayer Animal Health Gmbh Enhanced immune response in bovine species
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CN103721253B (zh) * 2014-01-02 2015-06-10 青岛易邦生物工程有限公司 一种禽脑脊髓炎和鸡痘二联活疫苗
JP6772065B2 (ja) * 2014-02-28 2020-10-21 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh 免疫賦活プラスミド
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
US20190233825A1 (en) * 2015-06-26 2019-08-01 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
CA2993883A1 (en) * 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in porcine species
US20190008952A1 (en) * 2015-07-31 2019-01-10 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
TWI759317B (zh) 2016-07-26 2022-04-01 德商拜耳動物保健有限公司 牛物種中增加的生育力
EP3701032A1 (en) * 2017-12-15 2020-09-02 Bayer Animal Health GmbH Immunostimulatory oligonucleotides
CN114467855A (zh) * 2022-01-14 2022-05-13 广东海大集团股份有限公司 一种多病因气囊炎雏鸡模型的构建方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4458630A (en) * 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
DE60012711T2 (de) * 1999-03-26 2005-08-18 Vical, Inc., San Diego Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
CA2395840A1 (en) * 1999-12-27 2001-07-05 The University Of Manitoba Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US8945590B2 (en) * 2008-03-25 2015-02-03 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)

Also Published As

Publication number Publication date
US20120064151A1 (en) 2012-03-15
EP2992899B1 (en) 2020-07-01
AU2010246652A1 (en) 2011-11-17
KR20120027345A (ko) 2012-03-21
PE20120903A1 (es) 2012-08-01
CN102427827B (zh) 2015-07-22
SI2429581T1 (sl) 2015-11-30
PT2992899T (pt) 2020-09-21
UA106076C2 (uk) 2014-07-25
SI2992899T1 (sl) 2020-10-30
TWI555846B (zh) 2016-11-01
MX2011011931A (es) 2011-12-06
DK2429581T3 (en) 2015-11-09
DK2992899T3 (da) 2020-09-14
ES2808827T3 (es) 2021-03-02
JP5679589B2 (ja) 2015-03-04
HRP20201554T1 (hr) 2020-12-11
TW201043698A (en) 2010-12-16
HK1168032A1 (zh) 2012-12-21
RU2570732C2 (ru) 2015-12-10
ECSP11011448A (es) 2011-12-30
CL2011002808A1 (es) 2012-07-13
LT2992899T (lt) 2020-10-26
WO2010130374A1 (en) 2010-11-18
HRP20151117T1 (hr) 2015-11-20
EP2992899A1 (en) 2016-03-09
ZA201107827B (en) 2012-12-27
AR076767A1 (es) 2011-07-06
PL2429581T3 (pl) 2016-01-29
CO6460752A2 (es) 2012-06-15
MX336019B (es) 2016-01-06
BRPI1010803A2 (pt) 2018-06-12
JP2012526734A (ja) 2012-11-01
CA2761736C (en) 2017-09-26
CN104906573A (zh) 2015-09-16
PT2429581E (pt) 2015-11-02
KR101966989B1 (ko) 2019-04-08
EP2429581A1 (en) 2012-03-21
MY162561A (en) 2017-06-30
IL215900A (en) 2017-07-31
HUE025765T2 (en) 2016-05-30
HUE051005T2 (hu) 2021-01-28
CN102427827A (zh) 2012-04-25
IL215900A0 (en) 2012-01-31
UY32634A (es) 2010-12-31
AU2010246652B2 (en) 2014-10-02
EP2429581B1 (en) 2015-08-05
PL2992899T3 (pl) 2021-04-06
ES2550181T3 (es) 2015-11-05
RU2011150529A (ru) 2013-06-20
RU2570732C9 (ru) 2016-09-10
SV2011004056A (es) 2012-03-14
CA2761736A1 (en) 2010-11-18
NZ596366A (en) 2013-12-20
CR20110595A (es) 2012-03-09
KR20170102379A (ko) 2017-09-08

Similar Documents

Publication Publication Date Title
NI201100196A (es) Respuesta inmunitaria reforzada en especies aviares
CO6761354A2 (es) Respuesta inmune potenciada en la especie bovina
DOP2018000188A (es) Repelente de insectos
DOP2016000013A (es) Repelente de insectos
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
CO2018002207A2 (es) Composiciones contra alergia a los gatos
CL2012000168A1 (es) Compuesto derivado de carboxamida; una composición pesticida que lo comprende; uso de dicho compuesto para controlar plagas y parásitos animales.
BR112018077210A2 (pt) vírus de enterite de pato e usos do mesmo
CR20160026A (es) Composición repelente de nematodos
BRPI0924842A2 (pt) Carne e ovos de aves compreendendo ácidos graxos benéficos
CL2012002654A1 (es) Compuesto de propilmetilfenol o una composicion que lo comprende para tratar septicemia rickettsial salmonidea (srs) y/o enfermedades causadas por la piscirickettsia salmonis.
UY34268A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta
CL2013001594A1 (es) Articulo absorbente que comprende un compuesto de estimulo; un compuesto de estimulo; y metodo para hacer un compuesto de estimulo.
BR112015027078A2 (pt) produto comestível de origem animal e seu método de preparação
NI201300058A (es) Respuesta inmune potenciada en la especie bovina
UY34267A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta
BR112017016181A2 (pt) mdv1 recombinante e usos do mesmo
BR112013012482A8 (pt) Modelo de desafio para leishmaniose canina por picadas de mosquito-palha
WO2009117736A3 (en) Avian virus vaccines and uses thereof
UY35706A (es) Vacuna contra nematodos de ovinos
UY34266A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta
TH1401006386A (th) องค์ประกอบที่มีฤทธิ์ฆ่าศัตรูพืชและสัตว์ และ กรรมวิธีการที่เกี่ยวข้องกับมัน
CL2014003096A1 (es) Péptidos que inducen en peces una respuesta inmune contra copépodos y/o un escudo mucoso; vacunas; usos y métodos para modular la respuesta inmune de un pez y/o inducir la generación de un escudo mucoso.
TH163297B (th) ผลิตภัณฑ์ขับไล่แมลงรบกวน และวิธีการขับไล่แมลงรบกวน